Compare IDEXX Laboratories, Inc. (IDXX) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Palantir Technologies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while Palantir Technologies Inc trades at $205.67 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 11.8× IDEXX Laboratories, Inc.'s market cap, and Palantir Technologies Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Palantir Technologies Inc for 78 Days on average.
| IDXX | PLTR | |
|---|---|---|
Market Cap | $40.43B | $477.68B |
Volume | 692,164 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $766.68 | $207.18 |
52-Week Low | $504.70 | $107.27 |
Typical Hold Time | 46 Days | 78 Days |
Enterprise Value | $41.32B | $468.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Palantir (PLTR) trades at $205.71, up 6.01% with strong bullish momentum. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025 and net income margin expanding to 36.3%. Technical indicators signal bullish sentiment with the price approaching resistance at $206. Recent partnership with Armada for sovereign AI infrastructure and consistent earnings beats highlight the company's growth trajectory.
Palantir presents compelling growth prospects driven by AI platform adoption, though premium valuations (P/E 169.9, P/S 83.02) warrant caution. Analyst consensus remains positive with 54% buy ratings and $191.69 price target. Key risks include valuation sensitivity and competitive pressures in the AI software space. The company's strong cash flow generation and expanding commercial customer base support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
